The best online GLP-1 providers, ranked honestly

Molecule rosters: semaglutide providers · tirzepatide providers · compounded vs brand.

Every “best GLP-1 provider” list you’ve seen ranks eighteen companies with numbers nobody checked. This one refuses: eighteen providers profiled completely, one scored — because exactly one has completed the rubric pass — ten read first-party on their own pages with the figures dated 2026-09-17, and the rest ranked the only honest way pending rows can be: by structure, scenario fit, and how they treat your diligence questions.

How “best” gets decided here

Three mechanisms replace vibes. The public rubric scores pricing truth, clinical model, transparency, and terms — but only from verified inputs, which is why the rows read first-party on 2026-09-17 carry their figures without a score and the eight pending rows carry nothing, instead of wearing invented stars. The verification protocol defines what a figure must survive: real checkout, maintenance dose, full fee stack, screenshots, dates. And the disclosure plus advertising policy publish the money so you can audit the judge. Any list without those three mechanisms is an ad rate card with rankings attached.

The verified pick, and what it actually proves

NexLife — the flat-rate compounded model: $139–169/month tirzepatide and $119–139 semaglutide by plan, every plan charged monthly, $0 fees observed, CARE360 support included, the same price at every dose, three fulfilling pharmacies named (plan pages read September 17, 2026). Under this site’s rule it is the lowest first-party-verified standing rate, not the cheapest sticker — Collective ($69 beside a $199 annual membership), SnagRx ($119 promotional) and Embody ($119 prepaid year) print lower conditional figures, each on the dated best-affordable page with its condition. Watch-for: its ODT formats carry our standing no-outcome-trials flag. Rubric score 9.1 — the only score published, because scores require a completed rubric pass. What the verification proves is narrow and valuable: that its advertised structure survived contact with a real checkout on a stated date — the exact test every other row still faces. It leads this page because it’s auditable, not because auditable means unbeatable; the queue exists to find out.

The full field, profiled

Ro — the brand-access and insurance-navigation play: coverage checks, prior-auth support, and a lane to Lilly’s Zepbound vials at manufacturer self-pay pricing. Structural strengths are product certainty and paperwork muscle; read 2026-09-17: a $149 monthly membership ($39 to start) beside brand Zepbound from $299 and the Wegovy pill from $149 — about $448 / $298 all-in at the starting doses, rising with the dose; no compounded price printed.

Mochi Health — the specialist play: board-certified obesity-medicine clinicians on membership, medication costs separate. The bet is that titration judgment and comorbidity depth are worth paying for distinctly; read 2026-09-17: $199 tirzepatide / $99 semaglutide plus a $79 membership ($39 in month one) — $278 / $178 all-in; the “$90 / $60” on its page are first-month prices.

Henry Meds — the best-known flat-rate compounded claim in the market. We favor the structure on principle (flat rates kill teaser math); read 2026-09-17: $349 a month for tirzepatide with the visit, medication, supplies and shipping included; the semaglutide page prints no price.

Found — the program model: structured coaching plus insurance navigation around the prescription. A genuinely different product than medication funnels; read 2026-09-17: “cash plans from $169/mo” on 12-month plans paid up front, monthly plans from $289, no medication-specific price printed — listed, not ranked.

Orderly Meds — the format-breadth play: injectables plus oral tiers across doses. Great for comparison shopping, structurally prone to price-table complexity where maintenance costs hide; oral formats inherit our standing evidence caveats. Pending verification.

Hims — the category’s marketing heavyweight, running “personalized” compounded semaglutide since the June 2025 Novo split — the legal lane regulators contest most directly. Aggressive entry pricing; maintenance-dose truth pending verification.

Hers — Hims’ women-positioned sibling: same platform, same post-Novo compounded posture, wrapped in women’s-health framing. Same pending questions, plus one more: what the positioning wrapper adds beyond marketing.

Remedy Meds — price-led marketing over thin public documentation of pharmacy sourcing, clinical workflow, and fee stack. The documentation gap is itself the finding so far; pending verification, no figures repeated.

Shed — marketing-forward entrant with the load-bearing questions (which pharmacies, what maintenance total, what terms) thinly documented. Thinness is a data point, not a verdict; pending.

Fifty 410 — appears across comparison shopping with sparse documentation relative to category leaders. Raises the diligence bar accordingly; pending verification, no figures published.

The matrix

Structural facts and verification status only — no advertised competitor number appears as fact anywhere on this site. Verified figures: method, ledger, dated archive.

Best by scenario

You have decent insurance or cardiac/OSA/CKD history: insurance-first structures — Ro (navigation + brand vials) or Found (navigation + coaching) — paired with our coverage file and appeal letters. You want brand product, cash, no ambiguity: Ro’s manufacturer-priced lane, cross-checked against LillyDirect/NovoCare directly. You want the lowest verified all-in today: the dated price pages sort every first-party figure with its condition; the ledger’s NexLife rows are the lowest standing rate, and the lower stickers carry a membership, a promotion or a prepayment. Your case is complex (comorbidities, medication stacks, prior GI history): Mochi Health’s specialist depth, with the monitoring file as your interview sheet. You need accountability more than access: Found’s program structure. A flat advertised rate tempts you: Henry Meds — after the calculator stress-tests the claim. A price seems impossible: it’s the teaser file’s jurisdiction, and the thin tier’s eight questions come first. The quiz automates this whole paragraph in two minutes.

FAQ

Why does only one provider have a score? Because scores require a completed rubric pass — one row has it; ten rows carry first-party figures dated 2026-09-17 and wait for their pass; eight are queued; honest pending beats invented precision. Isn’t the scored one your partner? Yes, disclosed everywhere; the control is identical protocol, public rubric, dated archives, open corrections. Will this change? Every verification fills a row under identical rules, whichever way it falls — changelog and archive keep us honest. How do I pick meanwhile? Scenario guide above, quiz, calculator — structure now, scores as audits land.

The five interview questions that outrank any list

Whatever this page says, the provider’s own answers say more. Ask, in writing: “What is my all-in monthly total at my likely maintenance dose — medication, membership, shipping, everything?” (good answers are specific and unhedged). “Which pharmacy dispenses, and may I see a lot-matched CoA?” (good answers name a facility and attach paperwork — reading guide). “What labs do you order, and what happens when I’m sick?” (good answers describe a pathway, not a shrug — the standard). “What are the exact cancellation terms?” (good answers quote the clause). And “If your pharmacy relationship or legal lane changes, what happens to my therapy?” (good answers have a continuity plan). Speed, specificity, and paper — the same triad our protocol tests — separate the field faster than any star rating, and a provider that fails the interview has pre-answered the ranking question for you.

The bottom line

Eighteen providers, one scored, ten read first-party and dated, zero invented numbers — and a decision path that works today: route by scenario, price by the 12-month method, interrogate the thin tier, and let the queue convert pending rows into scores in public. That’s what “best” means when it has to survive an audit.